115 related articles for article (PubMed ID: 37286404)
1. Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance.
Zambrano IA; Hwang S; Basak R; Spratte BN; Filson CP; Jacobs BL; Tan HJ
Urol Oncol; 2023 Sep; 41(9):388.e1-388.e8. PubMed ID: 37286404
[TBL] [Abstract][Full Text] [Related]
2. Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?
Spratte BN; Tan HJ; Zambrano IA; Basak RS; Filson CP; Jacobs BL; Hwang S
Urol Oncol; 2023 Jul; 41(7):323.e17-323.e25. PubMed ID: 37149430
[TBL] [Abstract][Full Text] [Related]
3. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
4. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
[TBL] [Abstract][Full Text] [Related]
5. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
6. The Influence of Practice Structure on Urologists' Treatment of Men With Low-Risk Prostate Cancer.
Mitchell JM; Gresenz CR
Med Care; 2022 Sep; 60(9):665-672. PubMed ID: 35880758
[TBL] [Abstract][Full Text] [Related]
7. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
8. Understanding Active Surveillance for Prostate Cancer.
Lai LY; Shahinian VB; Oerline MK; Kaufman SR; Skolarus TA; Caram MEV; Hollenbeck BK
JCO Oncol Pract; 2021 Nov; 17(11):e1678-e1687. PubMed ID: 33830822
[TBL] [Abstract][Full Text] [Related]
9. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
[TBL] [Abstract][Full Text] [Related]
10. Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees.
Marchetti KA; Oerline M; Hollenbeck BK; Kaufman SR; Skolarus TA; Shahinian VB; Caram MEV; Modi PK
Urology; 2021 Sep; 155():77-82. PubMed ID: 33610652
[TBL] [Abstract][Full Text] [Related]
11. Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Borza T; Schroeck FR; Jacobs BL; Skolarus TA; Shahinian VB
Eur Urol; 2018 Apr; 73(4):491-498. PubMed ID: 28823605
[TBL] [Abstract][Full Text] [Related]
12. Racial Disparities in Active Surveillance for Prostate Cancer.
Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
[TBL] [Abstract][Full Text] [Related]
13. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Shah ND; Meropol NJ; Tilburt JC; Nguyen PL; Yu JB; Abouassaly R; Kim A; Gross CP
Eur Urol Oncol; 2019 Mar; 2(2):189-195. PubMed ID: 31017095
[TBL] [Abstract][Full Text] [Related]
14. Health care delivery system contributions to management of newly diagnosed prostate cancer.
Krampe N; Kaufman SR; Oerline MK; Hill D; Caram MEV; Shahinian VB; Hollenbeck BK; Maganty A
Cancer Med; 2023 Aug; 12(16):17346-17355. PubMed ID: 37475511
[TBL] [Abstract][Full Text] [Related]
15. Population-based assessment of determining predictors for quality of prostate cancer surveillance.
Chamie K; Williams SB; Hershman DL; Wright JD; Nguyen PL; Hu JC
Cancer; 2015 Dec; 121(23):4150-7. PubMed ID: 26307939
[TBL] [Abstract][Full Text] [Related]
16. Urologist Practice Structure and Spending for Prostate Cancer Care.
Modi PK; Herrel LA; Kaufman SR; Yan P; Borza T; Skolarus TA; Schroeck FR; Hollenbeck BK; Shahinian VB
Urology; 2019 Aug; 130():65-71. PubMed ID: 31029672
[TBL] [Abstract][Full Text] [Related]
17. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
18. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Gross CP; Nguyen PL; Smaldone MC; Shah ND; Karnes RJ; Thompson RH; Han LC; Yu JB; Trinh QD; Ziegenfuss JY; Sun M; Tilburt JC
Med Care; 2014 Jul; 52(7):579-85. PubMed ID: 24926704
[TBL] [Abstract][Full Text] [Related]
19. A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
Kato T; Tohi Y; Honda T; Matsuda I; Osaki Y; Naito H; Matsuoka Y; Okazoe H; Taoka R; Tsunemori H; Ueda N; Sugimoto M
Int J Urol; 2023 Mar; 30(3):289-297. PubMed ID: 36415128
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions.
Ramsey SD; Zeliadt SB; Fedorenko CR; Blough DK; Moinpour CM; Hall IJ; Smith JL; Ekwueme DU; Fairweather ME; Thompson IM; Keane TE; Penson DF
World J Urol; 2011 Feb; 29(1):3-9. PubMed ID: 20959991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
